Adjuvant and neoadjuvant therapy for pancreatic cancer

Shimpei Maeda, Michiaki Unno, Jun Yu

Research output: Contribution to journalReview articlepeer-review


Pancreatic cancer still remains a major cause of cancer-related mortality; however, there is a slight but continuous improvement in survival over the past 2 decades. Progress in chemotherapy has contributed to the survival improvement in patients with any stage of pancreatic cancer. In this review, we summarize the currently available evidence regarding adjuvant and neoadjuvant therapy with a focus mainly on randomized controlled trial. The median overall survival in resected pancreatic cancer patients has significantly improved to 22.8 to 54.4 months with the use of adjuvant therapy from 11 to 20.2 months with a strategy of observation only. Recent data from randomized trials support the use of neoadjuvant therapy for patients with resectable or borderline resectable pancreatic cancer. But given a variety of neoadjuvant regimens and different definitions of resectability status, data should be interpreted with caution. Several other trials are ongoing and will provide further evidence.

Original languageEnglish (US)
Pages (from-to)100-106
Number of pages7
JournalJournal of Pancreatology
Issue number3
StatePublished - Sep 2019


  • Adjuvant therapy
  • Chemotherapy
  • Neoadjuvant therapy
  • Pancreatic cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology


Dive into the research topics of 'Adjuvant and neoadjuvant therapy for pancreatic cancer'. Together they form a unique fingerprint.

Cite this